Drug Trial Radar · NCT07674615
IMMU-132 in TROP-2 Overexpressed Advanced and Relapsed Ovarian Cancer
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
19
Planned (sponsor's estimate)
Start
Sep 2, 2026
Primary completion
Jun 30, 2027
Study completion Jun 30, 2027
Sponsor
- Lead sponsor
- Shanghai Gynecologic Oncology GroupGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- First posted
- Jun 29, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To observe the efficacy and safety of IMMU-132 in patients with advanced or recurrent ovarian cancer with high TROP-2 expression in tumor tissue, who have failed standard therapy or are unable to receive standard treatment.
Conditions
- Epithelial Ovarian Cancer
- Fallopian Tube Cancers
- Primary
- Primary Peritoneal Carcinoma
Interventions
Sacituzumab govitecan monotherapyDrug
Sacituzumab govitecan monotherapy at a dose of 10 mg/kg administered intravenously on Days 1 and 8 of each 21-day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rateTime frame: 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Zhongshan Hospital Fudan University
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.